vVARDIS, a Swiss healthcare company that provides solutions for dental professionals, has secured a total of $85 million in financing to expand the rollout of Curodont™, its drill-free early tooth decay treatment, states a July 15, 2025, press release from the company. After acquiring an initial 35 million from healthcare investment firm OrbiMed in February 2025, a follow-up funding round that recently closed produced an additional $50 million. The total capital of $85 million will be used to refinance existing facilities, support the company's growth initiatives, and continue the global commercial expansion of innovative dental products under the Curodont™ brand.
“After our initial investment, we've seen firsthand the momentum vVARDIS is building in the dental market with its Curodont™ products,” says Matthew Rizzo, general partner, OrbiMed. “We came in at a pivotal moment—just as the product began gaining real traction—and the company's rapid progress and the market's response have since reinforced our belief in the significant opportunities ahead. That's why we're excited to deepen our commitment and expand our investment to support vVARDIS in its next phase of growth.”
According to the World Health Organization, tooth decay remains the number one noncommunicable disease in the world. As partners, vVARDIS and OrbiMed have a shared vision to address this epidemic by becoming a US and global leader in innovative dental products. As dentistry’s paradigm shifts from the provision of invasive to minimally invasive care and the development and adoption of AI-powered early tooth decay systems accelerates, vVARDIS products are well-timed to enable dental practices to treat early tooth decay within minutes, without needles or drills, saving time for patients and dental professionals alike. The press release notes that a rapid expansion of sales in 2024, which resulted in more than a million teeth being treated in the United States, has driven nearly 10% of US practices to purchase the product and enabled the treatment of 400,000 patients since 2024.
“We are thrilled to expand our partnership with OrbiMed as we enter this next phase of growth,” said Drs. Haley and Goly Abivardi, the founders and co-CEOs of vVARDIS. “With Curodont™ now offered in nearly 10% of US dental offices, it's clear dental professionals are embracing our solution for early decay. This additional funding, combined with OrbiMed's strategic expertise, will accelerate our ability to serve dental professionals and patients globally. As dentists, we are delighted to bring forward a drill-free treatment for early decay that promises to elevate the standard of care for patients around the world.”
